Alan B Schorr | Philadelphia College of Osteopathic Medicine (original) (raw)

Papers by Alan B Schorr

Research paper thumbnail of 484: Evaluation of Glycemic Control with Endotool Glucose Management System for Insulin Infusion Therapy

Critical Care Medicine, 2016

Research paper thumbnail of Is adiposopathy an endocrine disease

International Journal of Clinical Practice, Oct 14, 2008

Research paper thumbnail of AACE/AAES MEDICAL/SURGICAL Guidelines for Clinical Practice: Management of Thyroid Carcinoma

Research paper thumbnail of Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity

Expert Review of Cardiovascular Therapy, 2008

Research paper thumbnail of Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial

The lancet. Diabetes & endocrinology, Jan 13, 2017

Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor approved for the treatment of type 2 ... more Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor approved for the treatment of type 2 diabetes. We aimed to assess the efficacy and safety of dapagliflozin as an add-on to adjustable insulin in patients with inadequately controlled type 1 diabetes. DEPICT-1 was a double-blind, randomised, parallel-controlled, three-arm, phase 3, multicentre study done at 143 sites in 17 countries. Eligible patients were aged 18-75 years and had inadequately controlled type 1 diabetes (HbA1c between ≥7·7% and ≤11·0% [≥61·0 mmol/mol and ≤97·0 mmol/mol]) and had been prescribed insulin for at least 12 months before enrolment. After an 8 week lead-in period to optimise diabetes management, patients were randomly assigned (1:1:1) using an interactive voice response system to dapagliflozin 5 mg or 10 mg once daily, given orally, or matched placebo. Randomisation was stratified by current use of continuous glucose monitoring, method of insulin administration, and baseline HbA1c. The primary effi...

Research paper thumbnail of Aspiration therapy for the treatment of obesity: 4-year results of a multicenter randomized controlled trial

Surgery for Obesity and Related Diseases

Research paper thumbnail of Newer Modalities in the Treatment of Type 2 Diabetes Mellitus: Focus on Technology

Type 2 Diabetes [Working Title]

This chapter will focus on the technological advances for individuals with Type 2 diabetes mellit... more This chapter will focus on the technological advances for individuals with Type 2 diabetes mellitus and their effect on treatment, control of blood glucoses and possible improvement in lifestyle and decreasing complications. This is a general overview of technological improvements and not an outline for specific patient care. Various technologies will be discussed and the outlook for future improvements outlined.

Research paper thumbnail of Aspiration Therapy for the Treatment of Obesity: 2-4 Year Results of the PATHWAY Multicenter Randomized Controlled Trial

Surgery for Obesity and Related Diseases

Research paper thumbnail of Control of Hyperglycemia with Hyperalimentation Solutions Containing Insulin

Journal of Pharmacy Technology

Research paper thumbnail of Percutaneous Gastrostomy Device for the Treatment of Class II and Class III Obesity: Results of a Randomized Controlled Trial

The American journal of gastroenterology, Mar 6, 2016

The AspireAssist System (AspireAssist) is an endoscopic weight loss device that is comprised of a... more The AspireAssist System (AspireAssist) is an endoscopic weight loss device that is comprised of an endoscopically placed percutaneous gastrostomy tube and an external device to facilitate drainage of about 30% of the calories consumed in a meal, in conjunction with lifestyle (diet and exercise) counseling. In this 52-week clinical trial, 207 participants with a body-mass index (BMI) of 35.0-55.0 kg/m(2) were randomly assigned in a 2:1 ratio to treatment with AspireAssist plus Lifestyle Counseling (n=137; mean BMI was 42.2±5.1 kg/m(2)) or Lifestyle Counseling alone (n=70; mean BMI was 40.9±3.9 kg/m(2)). The co-primary end points were mean percent excess weight loss and the proportion of participants who achieved at least a 25% excess weight loss. At 52 weeks, participants in the AspireAssist group, on a modified intent-to-treat basis, had lost a mean (±s.d.) of 31.5±26.7% of their excess body weight (12.1±9.6% total body weight), whereas those in the Lifestyle Counseling group had lo...

Research paper thumbnail of 381 The AspireAssist Is an Effective Tool in the Treatment of Class II and Class III Obesity: Results of a One-Year Clinical Trial

Research paper thumbnail of Complications of type 2 diabetes mellitus: a brief overview

The Journal of the American Osteopathic Association, 1999

The recent findings of the United Kingdom Prospective Diabetes Study (UKPDS) have focused attenti... more The recent findings of the United Kingdom Prospective Diabetes Study (UKPDS) have focused attention on the need to prevent complications in type 2 diabetes mellitus. Understanding the pathogenesis and physiologic mechanisms that lead to complications in the patients with type 2 diabetes mellitus is imperative to prevent their progression and improve treatment. This article discusses the more common complications and their possible etiologies, progression, and contribution to the morbidity of the diabetic population. It also reviews treatment of these complications and recent advances. In addition, some of the less common complications will be identified so that primary care physicians and specialists will be aware and not overlook these in patients who can be treated early and aggressively.

Research paper thumbnail of Simultaneous Use of Two External Subcutaneous Pumps Delivering Insulin and SYMLIN: Use of a Double-Pump System

Journal of Diabetes Science and Technology, 2012

Abbreviations: (HbA1c), hemoglobin A1c

Research paper thumbnail of Managing Type 2 Diabetes Mellitus Across the Disease Spectrum

The Journal of the American Osteopathic Association, 2014

Research paper thumbnail of Low Incidence of Painless Thyroiditis in the Philadelphia Area

Clinical Nuclear Medicine, 1986

Publications from the midwestern region of the United States have demonstrated an incidence of 14... more Publications from the midwestern region of the United States have demonstrated an incidence of 14-23% of painless thyroiditis in hyperthyroid individuals. This possibly could represent a local phenomenon, and perhaps is not typical for other areas of the country. The 24 hour radioactive iodine uptakes in 152 consecutive hyperthyroid individuals in the Philadelphia area were evaluated. No patient in the series, with clinical and biochemical evidence of hyperthyroidism, had painless thyroiditis. It is concluded that the incidence of painless thyroiditis is markedly lower in the Philadelphia area than in the Midwest regions of the United States.

Research paper thumbnail of Newer Modalities in the Treatment of Type 2 Diabetes Mellitus: Focus on Technology

Type 2 Diabetes [Working Title]

This chapter will focus on the technological advances for individuals with Type 2 diabetes mellit... more This chapter will focus on the technological advances for individuals with Type 2 diabetes mellitus and their effect on treatment, control of blood glucoses and possible improvement in lifestyle and decreasing complications. This is a general overview of technological improvements and not an outline for specific patient care. Various technologies will be discussed and the outlook for future improvements outlined.

Research paper thumbnail of Adiposopathy: Treating Pathogenic Adiposopathy: Treating Pathogenic Adipose Tissue to Reduce Adipose Tissue to Reduce Cardiovascular Disease Risk Cardiovascular Disease Risk

Current Treatment Options in Cardiovascular Medicine, 2007

Research paper thumbnail of Usability and training differences between two personal insulin pumps

Journal of diabetes science and technology, 2015

The purpose of this study was to determine if there were usability and training differences betwe... more The purpose of this study was to determine if there were usability and training differences between the Medtronic MiniMed Paradigm Revel™ Insulin Pump and the Tandem Diabetes Care t:slim® Insulin Pump during use by representative users, performing representative tasks, in a simulated use environment. This study utilized a between-subjects experimental design with a total of 72 participants from 5 sites across the United States. Study participants were randomized to either the Revel pump group or the t:slim Pump group. Participants were 18 years of age or older and managed their diabetes using multiple daily insulin injections. Dependent variables included training time, training satisfaction, time on task, task failures, System Usability Scale (SUS) ratings, perceived task difficulty, and a pump survey that measured different aspects of the pumps and training sessions. There was a statistically significant difference in training times and error rates between the t:slim and Revel gro...

Research paper thumbnail of Evaluation of treatment satisfaction associated with the use of insulin aspart in continuous subcutaneous insulin infusion

Diabetes technology & therapeutics, 2008

The purpose of this study was to compare treatment satisfaction among people with type 1 and type... more The purpose of this study was to compare treatment satisfaction among people with type 1 and type 2 diabetes after switching from insulin lispro to insulin aspart in continuous subcutaneous insulin infusion (CSII). Efficacy of glycemic control between treatments was also investigated. Subjects using CSII with insulin lispro for 6 months or longer continued this therapy over a 4-week period and then switched to insulin aspart in CSII for 12 weeks. The Diabetes Treatment Satisfaction Questionnaire (DTSQ) and Insulin Treatment Satisfaction Questionnaire (ITSQ) were administered immediately prior to the switch and again at the end of 12 weeks of therapy with insulin aspart. Hemoglobin A(1c)(A1C) and fasting blood glucose (FBG) levels, insulin dose, and body weight were recorded at the same time points. Although average overall DTSQ score did not change significantly, average overall ITSQ score was significantly improved following the insulin aspart treatment. There was a small but stati...

Research paper thumbnail of Adiposopathy: Treating pathogenic adipose tissue to reduce cardiovascular disease risk

Current Treatment Options in Cardiovascular Medicine, 2007

Excessive adipose tissue is potentially pathogenic due to its mass effects and through adverse me... more Excessive adipose tissue is potentially pathogenic due to its mass effects and through adverse metabolic/immune responses, which may lead to cardiovascular disease risk factors (eg, type 2 diabetes mellitus, hypertension, dyslipidemia, and possibly atherosclerosis itself). Positive caloric balance in genetically/environmentally susceptible patients may result in adipocyte hypertrophy, visceral adipose tissue accumulation, and ectopic fat deposition, all causally associated with metabolic disease, and all anatomic manifestations of "adiposopathy" (a term used to describe adipose tissue pathology). Weight loss through improved nutrition, increased physical activity, and weight loss agents (ie, orlistat and sibutramine) improves adiposopathy and improves many metabolic diseases whose prevalence are directly associated with an increase in body fat and sedentary lifestyle. Cannabinoid receptor antagonists improve adiposopathy through weight reduction and favorable metabolic effects upon multiple body organs (including adipocytes). Peroxisome proliferator-activated receptor-gamma agonists may improve adiposopathy through recruitment of functional fat cells and apoptosis of dysfunctional fat cells.

Research paper thumbnail of 484: Evaluation of Glycemic Control with Endotool Glucose Management System for Insulin Infusion Therapy

Critical Care Medicine, 2016

Research paper thumbnail of Is adiposopathy an endocrine disease

International Journal of Clinical Practice, Oct 14, 2008

Research paper thumbnail of AACE/AAES MEDICAL/SURGICAL Guidelines for Clinical Practice: Management of Thyroid Carcinoma

Research paper thumbnail of Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity

Expert Review of Cardiovascular Therapy, 2008

Research paper thumbnail of Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial

The lancet. Diabetes & endocrinology, Jan 13, 2017

Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor approved for the treatment of type 2 ... more Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor approved for the treatment of type 2 diabetes. We aimed to assess the efficacy and safety of dapagliflozin as an add-on to adjustable insulin in patients with inadequately controlled type 1 diabetes. DEPICT-1 was a double-blind, randomised, parallel-controlled, three-arm, phase 3, multicentre study done at 143 sites in 17 countries. Eligible patients were aged 18-75 years and had inadequately controlled type 1 diabetes (HbA1c between ≥7·7% and ≤11·0% [≥61·0 mmol/mol and ≤97·0 mmol/mol]) and had been prescribed insulin for at least 12 months before enrolment. After an 8 week lead-in period to optimise diabetes management, patients were randomly assigned (1:1:1) using an interactive voice response system to dapagliflozin 5 mg or 10 mg once daily, given orally, or matched placebo. Randomisation was stratified by current use of continuous glucose monitoring, method of insulin administration, and baseline HbA1c. The primary effi...

Research paper thumbnail of Aspiration therapy for the treatment of obesity: 4-year results of a multicenter randomized controlled trial

Surgery for Obesity and Related Diseases

Research paper thumbnail of Newer Modalities in the Treatment of Type 2 Diabetes Mellitus: Focus on Technology

Type 2 Diabetes [Working Title]

This chapter will focus on the technological advances for individuals with Type 2 diabetes mellit... more This chapter will focus on the technological advances for individuals with Type 2 diabetes mellitus and their effect on treatment, control of blood glucoses and possible improvement in lifestyle and decreasing complications. This is a general overview of technological improvements and not an outline for specific patient care. Various technologies will be discussed and the outlook for future improvements outlined.

Research paper thumbnail of Aspiration Therapy for the Treatment of Obesity: 2-4 Year Results of the PATHWAY Multicenter Randomized Controlled Trial

Surgery for Obesity and Related Diseases

Research paper thumbnail of Control of Hyperglycemia with Hyperalimentation Solutions Containing Insulin

Journal of Pharmacy Technology

Research paper thumbnail of Percutaneous Gastrostomy Device for the Treatment of Class II and Class III Obesity: Results of a Randomized Controlled Trial

The American journal of gastroenterology, Mar 6, 2016

The AspireAssist System (AspireAssist) is an endoscopic weight loss device that is comprised of a... more The AspireAssist System (AspireAssist) is an endoscopic weight loss device that is comprised of an endoscopically placed percutaneous gastrostomy tube and an external device to facilitate drainage of about 30% of the calories consumed in a meal, in conjunction with lifestyle (diet and exercise) counseling. In this 52-week clinical trial, 207 participants with a body-mass index (BMI) of 35.0-55.0 kg/m(2) were randomly assigned in a 2:1 ratio to treatment with AspireAssist plus Lifestyle Counseling (n=137; mean BMI was 42.2±5.1 kg/m(2)) or Lifestyle Counseling alone (n=70; mean BMI was 40.9±3.9 kg/m(2)). The co-primary end points were mean percent excess weight loss and the proportion of participants who achieved at least a 25% excess weight loss. At 52 weeks, participants in the AspireAssist group, on a modified intent-to-treat basis, had lost a mean (±s.d.) of 31.5±26.7% of their excess body weight (12.1±9.6% total body weight), whereas those in the Lifestyle Counseling group had lo...

Research paper thumbnail of 381 The AspireAssist Is an Effective Tool in the Treatment of Class II and Class III Obesity: Results of a One-Year Clinical Trial

Research paper thumbnail of Complications of type 2 diabetes mellitus: a brief overview

The Journal of the American Osteopathic Association, 1999

The recent findings of the United Kingdom Prospective Diabetes Study (UKPDS) have focused attenti... more The recent findings of the United Kingdom Prospective Diabetes Study (UKPDS) have focused attention on the need to prevent complications in type 2 diabetes mellitus. Understanding the pathogenesis and physiologic mechanisms that lead to complications in the patients with type 2 diabetes mellitus is imperative to prevent their progression and improve treatment. This article discusses the more common complications and their possible etiologies, progression, and contribution to the morbidity of the diabetic population. It also reviews treatment of these complications and recent advances. In addition, some of the less common complications will be identified so that primary care physicians and specialists will be aware and not overlook these in patients who can be treated early and aggressively.

Research paper thumbnail of Simultaneous Use of Two External Subcutaneous Pumps Delivering Insulin and SYMLIN: Use of a Double-Pump System

Journal of Diabetes Science and Technology, 2012

Abbreviations: (HbA1c), hemoglobin A1c

Research paper thumbnail of Managing Type 2 Diabetes Mellitus Across the Disease Spectrum

The Journal of the American Osteopathic Association, 2014

Research paper thumbnail of Low Incidence of Painless Thyroiditis in the Philadelphia Area

Clinical Nuclear Medicine, 1986

Publications from the midwestern region of the United States have demonstrated an incidence of 14... more Publications from the midwestern region of the United States have demonstrated an incidence of 14-23% of painless thyroiditis in hyperthyroid individuals. This possibly could represent a local phenomenon, and perhaps is not typical for other areas of the country. The 24 hour radioactive iodine uptakes in 152 consecutive hyperthyroid individuals in the Philadelphia area were evaluated. No patient in the series, with clinical and biochemical evidence of hyperthyroidism, had painless thyroiditis. It is concluded that the incidence of painless thyroiditis is markedly lower in the Philadelphia area than in the Midwest regions of the United States.

Research paper thumbnail of Newer Modalities in the Treatment of Type 2 Diabetes Mellitus: Focus on Technology

Type 2 Diabetes [Working Title]

This chapter will focus on the technological advances for individuals with Type 2 diabetes mellit... more This chapter will focus on the technological advances for individuals with Type 2 diabetes mellitus and their effect on treatment, control of blood glucoses and possible improvement in lifestyle and decreasing complications. This is a general overview of technological improvements and not an outline for specific patient care. Various technologies will be discussed and the outlook for future improvements outlined.

Research paper thumbnail of Adiposopathy: Treating Pathogenic Adiposopathy: Treating Pathogenic Adipose Tissue to Reduce Adipose Tissue to Reduce Cardiovascular Disease Risk Cardiovascular Disease Risk

Current Treatment Options in Cardiovascular Medicine, 2007

Research paper thumbnail of Usability and training differences between two personal insulin pumps

Journal of diabetes science and technology, 2015

The purpose of this study was to determine if there were usability and training differences betwe... more The purpose of this study was to determine if there were usability and training differences between the Medtronic MiniMed Paradigm Revel™ Insulin Pump and the Tandem Diabetes Care t:slim® Insulin Pump during use by representative users, performing representative tasks, in a simulated use environment. This study utilized a between-subjects experimental design with a total of 72 participants from 5 sites across the United States. Study participants were randomized to either the Revel pump group or the t:slim Pump group. Participants were 18 years of age or older and managed their diabetes using multiple daily insulin injections. Dependent variables included training time, training satisfaction, time on task, task failures, System Usability Scale (SUS) ratings, perceived task difficulty, and a pump survey that measured different aspects of the pumps and training sessions. There was a statistically significant difference in training times and error rates between the t:slim and Revel gro...

Research paper thumbnail of Evaluation of treatment satisfaction associated with the use of insulin aspart in continuous subcutaneous insulin infusion

Diabetes technology & therapeutics, 2008

The purpose of this study was to compare treatment satisfaction among people with type 1 and type... more The purpose of this study was to compare treatment satisfaction among people with type 1 and type 2 diabetes after switching from insulin lispro to insulin aspart in continuous subcutaneous insulin infusion (CSII). Efficacy of glycemic control between treatments was also investigated. Subjects using CSII with insulin lispro for 6 months or longer continued this therapy over a 4-week period and then switched to insulin aspart in CSII for 12 weeks. The Diabetes Treatment Satisfaction Questionnaire (DTSQ) and Insulin Treatment Satisfaction Questionnaire (ITSQ) were administered immediately prior to the switch and again at the end of 12 weeks of therapy with insulin aspart. Hemoglobin A(1c)(A1C) and fasting blood glucose (FBG) levels, insulin dose, and body weight were recorded at the same time points. Although average overall DTSQ score did not change significantly, average overall ITSQ score was significantly improved following the insulin aspart treatment. There was a small but stati...

Research paper thumbnail of Adiposopathy: Treating pathogenic adipose tissue to reduce cardiovascular disease risk

Current Treatment Options in Cardiovascular Medicine, 2007

Excessive adipose tissue is potentially pathogenic due to its mass effects and through adverse me... more Excessive adipose tissue is potentially pathogenic due to its mass effects and through adverse metabolic/immune responses, which may lead to cardiovascular disease risk factors (eg, type 2 diabetes mellitus, hypertension, dyslipidemia, and possibly atherosclerosis itself). Positive caloric balance in genetically/environmentally susceptible patients may result in adipocyte hypertrophy, visceral adipose tissue accumulation, and ectopic fat deposition, all causally associated with metabolic disease, and all anatomic manifestations of "adiposopathy" (a term used to describe adipose tissue pathology). Weight loss through improved nutrition, increased physical activity, and weight loss agents (ie, orlistat and sibutramine) improves adiposopathy and improves many metabolic diseases whose prevalence are directly associated with an increase in body fat and sedentary lifestyle. Cannabinoid receptor antagonists improve adiposopathy through weight reduction and favorable metabolic effects upon multiple body organs (including adipocytes). Peroxisome proliferator-activated receptor-gamma agonists may improve adiposopathy through recruitment of functional fat cells and apoptosis of dysfunctional fat cells.